The Bascom Palmer program showcases neovascular, exudative, and degenerative eye diseases, and is designed for retina specialists, general ophthalmologists, and researchers.
Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration program, now in its 20th iteration, is a virtual event scheduled for February 10-11 that showcases all there is to know about neovascular, exudative, and degenerative eye diseases.
The presenters are all experts in their field from renowned institutions worldwide.
“The program will highlight the revolutionary pharmacotherapies now in development and clinical practice for the management of neovascular age-related macular edema, macular edema, diabetic retinopathy, retinopathy of prematurity, and inherited retinal degenerations with a special emphasis on the present and future financial impact of these drugs on clinical practices and Medicare,” according to the course co-directors Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD, all from the Bascom Palmer Eye Institute, University of Miami, Miami.
The course is designed for retina specialists, general ophthalmologists, and researchers, and will review the latest advances in imaging, translational research, and clinical trials with an emphasis on how these results will impact clinical ophthalmology.
“We will emphasize early phase clinical trials and recently completed studies focused on the treatment of a wide range of retinal diseases with special emphasis on age-related macular degeneration, diabetic retinopathy, uveitis, and retinal degenerations,” the co-directors explained.
Friday, February 10
The following are the general topics covered in both sessions. All times are Eastern Standard Time.
Welcome and Overview, Pre-Program Test
Session I: Non-Exudative AMD
Session II: Predicting Disease Progression in Non-Exudative AMD
10:50 am-12:30 pm
Session III: Therapies for Non-Exudative AMD
Session IV: Pegcetacoplan Results for the Treatment of GA: Derby and Oaks Trials
Session V: Panel Discussion on Translating the Results of Clinical Trials to the Real-World Treatment of Late Nonexudative AMD
Session VI: Exudative AMD
Saturday, February 11
Welcome and Overview
Session VII: Session VII: Emerging and Current Therapies for Exudative AMD
9:50 am-12:00 pm
Session VIII: Diabetic Retinopathy-Imaging and Treatment
Session IX: Faricimab in Retinal Vascular Diseases
Session X: Retinal Vascular Diseases and Uveitis
Session XI: Inherited Retinal Degenerations
When participants finish this course, they should be able to
To learn more about or register for the meeting, click here.